SCHEMBL29304129

SCHEMBL29304129

CO[C@H]1CC[C@@H](S(=O)(=O)NC(=O)c2cc(C3CC3)c(OCC3CCCC3)cc2F)CC1

nearest known ligand 0.87

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 20/20 0.87
▸ SCN5A Q14524 4/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29304130 1.00 SCN9A (0.87) SCN9ASCN5A
SCHEMBL16448514 0.93 SCN9A (1.00) SCN9ASCN5A
SCHEMBL30261377 0.88 SCN9A (0.72) SCN9A
SCHEMBL30261282 0.88 SCN9A (0.72) SCN9A
SCHEMBL30261437 0.88 SCN9A (0.72) SCN9A
SCHEMBL16448645 0.87 SCN9A (1.00) SCN9ASCN5A
SCHEMBL16448643 0.87 SCN9A (1.00) SCN9ASCN5A
SCHEMBL16448592 0.87 SCN9A (1.00) SCN9ASCN5A
SCHEMBL16448557 0.85 SCN9A (0.85) SCN9ASCN5A
SCHEMBL16435134 0.85 SCN9A (1.00) SCN9ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME GENENTECH, INC. (US) 2024-07-11 — — US disclosed
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME GENENTECH, INC. (US) 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME CACNA1I, CACNA1B, CACNA1C SCN9A 38/4885SCN5A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback